|
|
News Breaks | | | | September 28, 2012 | | 10:01 EDT |  | NVO | Novo Nordisk discontinues vatreptacog development
Novo Nordisk announced the decision to discontinue the development of vatreptacog alfa, a fast-acting recombinant factor VIIa analogue for haemophilia patients with inhibitors. The decision follows analysis of the data from the phase 3a trial adeptTM 2. On August 9, Novo Nordisk announced that a few patients in the trial had developed anti-drug antibodies to vatreptacog alfa, one patient with a potentially neutralising effect. | |
|
News For NVO From The Last 14 Days Check below for free stories on NVO the last two weeks. |
|
|
| There are no results for NVO |
|
|
|
|
|
|
